

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 March 2005 (31.03.2005)

PCT

(10) International Publication Number
WO 2005/027894 A1

(51) International Patent Classification⁷: **A61K 31/192**,
31/216, 31/455, 38/00

(74) Agent: **WOOD, David, J.**; Pfizer Research and Develop-
ment, Ramsgate Road, Kent, Sandwich, Kent CT13 9NJ
(GB).

(21) International Application Number:
PCT/IB2004/003063

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date:
14 September 2004 (14.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
528388 19 September 2003 (19.09.2003) NZ

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PFIZER
HEALTH AB** (SE/SE); S-112 87 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CUTFIELD,**
Wayne, Stephen [NZ/NZ]; Pfizer Global Research and
Development, European Pharma Patent, Department,
Ramsgate Road, Sandwich, Kent CT13 9NJ (NZ). **HOF-**
MAN, Paul, Leslie [NZ/NZ]; Pfizer Global Research
and Development, European Pharma Patent, Department,
Ramsgate Road, Sandwich, Kent CT13 9NJ (NZ). **VICK-**
ERS, Mark, Hedley [GB/NZ]; Pfizer Global Research
and Development, European Pharma Patent, Department,
Ramsgate Road, Sandwich, Kent CT13 9NJ (NZ).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **ENHANCED METHOD OF TREATMENT OF GROWTH DISORDERS**

(57) Abstract: The application relates to the treatment of conditions and diseases for which growth hormone is a desirable method of treatment, using free fatty acid regulators in combination with growth hormone. In particular, the present invention discloses an enhanced method of treatment of growth disorders as well as methods to prevent and/or reduce adverse consequences of growth hormone treatment.

BEST AVAILABLE COPY

WO 2005/027894 A1